NewAmsterdam Pharma to Join June Investor Conferences

NAARDEN, the Netherlands and MIAMI, May 29, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a biopharmaceutical company in its late stages of development, focuses on creating oral, non-statin treatments for cardiovascular disease (CVD) patients with high low-density lipoprotein cholesterol (LDL-C). These patients often find existing treatments either ineffective or intolerable. The company has announced its participation in two major upcoming investor conferences.

On June 5, 2024, NewAmsterdam will be represented at the Jefferies Global Healthcare Conference in New York City. The event will feature a fireside chat at 3:00 p.m. ET, led by Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer.

Following this, on June 10, 2024, the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach. During this event, Michael Davidson, M.D., the CEO, will deliver a corporate overview at 10:40 a.m. ET.

Both presentations will be streamed live via the investor relations section of NewAmsterdam's website at ir.newamsterdampharma.com. Post-event, recordings will be accessible on the same site.

About NewAmsterdam Pharma:

NewAmsterdam Pharma (Nasdaq: NAMS) is dedicated to enhancing patient care in those with metabolic diseases. These are areas where the current treatment options are inadequate or poorly tolerated. The company aims to address the substantial unmet need for effective, well-tolerated, and convenient treatments for reducing LDL cholesterol.

The company's primary focus is on obicetrapib, an oral, low-dose, once-daily CETP inhibitor. This treatment is currently being tested in several phase 3 trials, either alone or in combination with ezetimibe. The goal is to provide additional LDL-C lowering therapies to supplement statin treatments for patients at risk of CVD due to elevated LDL-C levels.

NewAmsterdam's mission is to provide better patient outcomes for those struggling with metabolic diseases, particularly where existing therapies fall short. Through its innovative approaches and commitment to research, the company seeks to fill critical gaps in treatment and improve the quality of life for many patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!